Research Group Succeeded in the Recovery of Skeletal Muscle Differentiation Worsen by Diabetes Mellitus with Oligodeoxynucleotide
- Share
- Tweet
- Send to email
Application of myoDN to improve the muscle differentiation deteriorated by diabetes mellitus
Tomohide Takaya, Shinshu University
myoDN recovers the impaired muscle differentiation of patients with type 1 and type 2 diabetes
Modified from Nakamura et al., Frontiers in Physiology (2021) 12: 679152
Tomohide Takaya, Assistant Professor of Faculty of Agriculture at Shinshu University, and his research group succeeded in recovering skeletal muscle differentiation worsen by diabetes mellitus using myoDN.
Skeletal muscle is an important organ which effects various functions such as energy metabolism and heat production. Though, it is known that muscle mass decreases in some patients with diabetes mellitus and it correlates to their mortality. It has been reported that the differentiation ability of myoblasts, which are the source of skeletal muscle, is impaired in diabetic patients, and this is thought to be one of the causes of muscle mass loss.
Takaya has recently reported that oligo-DNA (short single-strand DNA) derived from genome sequence of lactic acid bacteria promotes skeletal muscle differentiation by binding with nucleolin, a target protein in myoblasts. This "myogenetic oligo-DNA" (myoDN) is expected to be a candidate for nucleic acid drug for various muscle diseases. In this study, the researchers investigated whether myoDN improves myoblast differentiation, which is worsen by diabetes.
In the study, they used myoblasts isolated from healthy subjects, type 1 diabetics, and type 2 diabetics. Compared to healthy subjects, the myoblasts from diabetic patients had lower ability to differentiate into skeletal muscle. However, myoDN treatment recovered muscle differentiation, which was worsened by diabetes. In addition, myoDN reduced inflammatory responses which were induced by glucose and fatty acids increased in the blood of diabetic patients.
myoDN is considered to be a nucleic acid molecule that is effective in reducing muscle mass in diabetic patients. On the other hand, the analyses of multiple myoblasts revealed that the effects of myoDN vary among individuals, which is the next issue to be solved for clinical application.
This study has been published in Frontiers in Physiology on May 24, 2021. To read the full-text article, access https://www.frontiersin.org/articles/10.3389/fphys.2021.679152/full.
Title: Myogenetic oligodeoxynucleotide (myoDN) recovers the differentiation of skeletal muscle myoblasts deteriorated by diabetes mellitus
Author: Shunichi Nakamura1, Shinichi Yonekura2,3, Takeshi Shimosato1,2,3, Tomohide Takaya1,2,3*
1Department of Agriculture, Graduate School of Science and Technology, 2Department of Agricultural and Life Sciences, Faculty of Agriculture, 3Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
EurekAlert!: https://www.eurekalert.org/pub_releases/2021-05/su-sml052621.php
